Asia Pacific Anatomic Pathology Market

Market Introduction

The anatomic pathology is a significant part of the study and treatment of the diseases. Anatomic pathology is a broad field that includes decedent pathology, surgical pathology, cytopathology, neuropathology, and ophthalmic pathology. The anatomic pathology is usually performed in the medical laboratories of hospitals and diagnostics laboratories.

Asia Pacific Anatomic Pathology Strategic Insights

Strategic insights for the Asia Pacific Anatomic Pathology provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Anatomic Pathology Report Scope

Asia Pacific Anatomic Pathology Regional Insights

The geographic scope of the Asia Pacific Anatomic Pathology refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Asia Pacific anatomic pathology market is expected to reach US$ 5,697.76 million by 2028 from US$ 3,556.33 million in 2021; it is estimated to grow at a CAGR of 7.0% from 2021 to 2028. The growth of the market is attributed to a few key driving factors such as the rising number of clinical trials for anticancer drugs and growing development of new technologies and launch of products in anatomic pathology. However, the lack of skilled professionals and the implementation of stringent government regulations hinder the market growth.

The number of cancer diagnosis procedures performed worldwide is increasing with the rise in prevalence of the disease. Despite significant progress in cancer prevention, diagnosis, and treatment, there is a large unmet medical need for the treatments for major cancer types, such as lung, prostate, breast, etc. Clinical trials play an important role in medical advancements and the development of evidence-based healthcare. These trials have the potential to improve the standard of care for all individuals who are diagnosed with cancer. Many researchers are conducting clinical trials to test new treatments for both common and rare cancer types. The FDA has approved a total of 47 immunotherapies as of December 2019 that includes almost every major cancer type. These drugs are now the standard of care for many cancers. Clinical trials find better ways to prevent, diagnose, and treat cancer. As the result of medications approval after going through clinical trials, many cancer patients live longer with improved quality of life. Pathology plays an important role in every phase of clinical trials. Thus, the rising number of clinical trials for anticancer drugs is likely to support the growth of the anatomic pathology market in the coming years. There is huge scope for the integration of machine learning (ML) and artificial intelligence (AI)-based systems in medical streams, including anatomic pathology. Several anatomic pathology laboratories are becoming increasingly aware of the benefits of digitization and AI in practice. Moreover, recent technological advancements and regulatory approvals are encouraging the digitalization of laboratories operations to improve the speed and accuracy of processes. The properly designed AI-based tools hold great potential for improving the workflow efficiency and diagnostic accuracy in pathology. The AI technology has potential in advancing pathology imaging, which can allow greater precision in diagnosis, leading to more specific treatment.  Digital pathology, a growing subfield within anatomical pathology, uses digital technologies to streamline data collection and management. Additionally, the digital pathology can reduce sample-to-result turnaround time and streamline the central pathology review process, further offering opportunities to increase trial efficiency. Various players operating in the market are focused on bringing innovative solutions for patients. Further, RadNet, an imaging services provider, and Hologic, a diagnostic products developer, collaborated on the development of AI tools for breast health. Thus, the introduction of new technologies and products is likely to emerge as a significant trend in the anatomic pathology market during the forecast period.

Countries in Asia Pacific are witnessing a massive challenges due to the growing cases of COVID-19. Considering the economic operations and geographic conditions, the outbreak of the disease has adversely affected medical tourism and diagnostic kits and drugs manufacturing, supply chains, and distribution. It caused other problems due to the shortage of healthcare infrastructure in low-income countries in the region. To prevent the spread of the novel coronavirus, restrictive measures have been taken in countries such as India, South Korea, Singapore, Malaysia, and the Philippines. The measures have disrupted all industries, such as cancer diagnostics. According to a recent article published by National Institute of Health, in April 2020, cancer patients admitted at hospitals in Delhi, India, are facing immense hardships as their treatments and diagnosis and progress checking tests have been postponed as hospitals are busy dealing with COVID-19 cases. Moreover, in India, the outbreak embarked upon the already vulnerable laboratories with challenges related to the availability of workforce, transportation, deficiency of personal protective equipment and gadgets, delay in procurement of essential items, a decline in financial turnover, and apprehensions among the staff. Some laboratory sections worked round the clock during lockdown to provide diagnostic facilities to routine and COVID-19 cases. Also, histopathology and cytology workload reduced substantially, which hampered the Asia Pacific anatomic pathology market growth.

Key Market Segments

Based on product and service, the Asia Pacific anatomic pathology market is segmented into instruments, consumables, and services. The services segment held the largest share of the market in 2021, whereas the instruments segment is anticipated to register the highest CAGR of the market during the forecast period.

By application, the Asia Pacific anatomic pathology market is segmented into disease diagnosis, drug discovery and development, and others. The disease diagnosis segment held the largest market share in 2021. However, the drug discovery and development segment is anticipated to register the highest CAGR of the market during 2021–2028.

The Asia Pacific anatomic pathology market, based on end user, is segmented into hospitals, research laboratories, diagnostic laboratories, and others. The others segment consists of pharmaceutical and biotechnology companies and contract research organizations (CROs). The hospitals segment held the largest share of the market in 2021, and the diagnostic laboratories segment is anticipated to register the highest CAGR of the market during the forecast period.

Major Sources and Companies Listed

A few of the primary and secondary sources  referred to while preparing the report on the Asia Pacific anatomic pathology market are the Indian Society of Nephrology (ISN), Korean Diabetes Association (KDA), Japan Association for Diabetes Education and Care (JADEC). and National Center for Biotechnology Information (NCBI).

Reasons to buy the report

• Determine prospective investment areas based on a detailed trend analysis of Asia Pacific anatomic pathology market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
• Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels driving the Asia Pacific anatomic pathology market, providing a clear picture of future opportunities that will help analyze, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Asia Pacific anatomic pathology market.

ASIA PACIFIC ANATOMIC PATHOLOGY MARKET SEGMENTATION

By

Product

s and Services

• Services
• Consumables
• Instruments

By

Application

• Disease Diagnosis
• Drug Discovery and Development
• Others

By End User

• Hospitals
• Research Laboratories
• Diagnostic Laboratories
• Others

By Country

• India
• Japan
• South Korea
• Australia
• China
• Rest of Asia Pacific

Company Profiles

• F. HOFFMANN-LA ROCHE LTD.
• Danaher
• Hologic, Inc.
• Agilent Technologies, Inc.
• BioGenex
• Diapath S.p.A.
• Bio SB
• MERCK KGaA
• BD
• PHC Holdings Corporation